Brief: Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo Study
24/04/2026 02:29
April 24 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX: RECEIVES FINAL EMA SCIENTIFIC ADVICE FOR PIVOTAL PHASE III VITILIGO STUDY CUV107 STUDY TO COMMENCE IN 2H 2026 Further company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist